Sonoma Pharmaceuticals (SNOA) Tax Provisions (2016 - 2026)
Sonoma Pharmaceuticals' (SNOA) quarterly Tax Provisions came in at $84000.0 in Q1 2026, down 66.13% year-on-year from $248000.0 in Q1 2025, and up 164.62% quarter-over-quarter from -$130000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Tax Provisions (2016 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Tax Provisions history runs 9 years deep, the most recent figure standing at $84000.0 for Q1 2026.
- On a quarterly basis, Tax Provisions fell 66.13% year-over-year to $84000.0 in Q1 2026; TTM through Mar 2026 was -$244000.0, a 144.36% decrease from a year earlier, with the FY2026 full-year figure at -$244000.0, down 144.36% from the prior year.
- Tax Provisions rose to $84000.0 in Q1 2026 per SNOA's latest filing, from -$130000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $471000.0 in Q1 2022 and bottomed at -$292000.0 in Q1 2024.
- The 5-year median for Tax Provisions is $9000.0 (2024), against an average of $32294.1.
- Across the five-year window, Tax Provisions soared 1900.0% in 2022 and plunged 1544.44% in 2025, its largest moves.
- Year by year, Tax Provisions stood at $34000.0 in 2022, then slumped by 267.65% to -$57000.0 in 2023, then surged by 115.79% to $9000.0 in 2024, then plunged by 1544.44% to -$130000.0 in 2025, then jumped by 164.62% to $84000.0 in 2026.
- Per Business Quant, the three latest SNOA Tax Provisions figures stand at $84000.0 (Q1 2026), -$130000.0 (Q4 2025), and -$197000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 67.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 157.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 676.90 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 43.40 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -423.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 48.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 30.00 Mn |
| 10 | Sonoma Pharmaceuticals | 179.80 | -2.40 Mn | 2.18 Mn | 84,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84,000.00 |
| Dec 31, 2025 | -130,000.00 |
| Sep 30, 2025 | -197,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Mar 31, 2025 | 248,000.00 |
| Dec 31, 2024 | 9,000.00 |
| Sep 30, 2024 | 147,000.00 |
| Jun 30, 2024 | 146,000.00 |
| Mar 31, 2024 | -292,000.00 |
| Dec 31, 2023 | -57,000.00 |
| Sep 30, 2023 | 186,000.00 |
| Jun 30, 2023 | -33,000.00 |
| Mar 31, 2023 | -131,000.00 |
| Dec 31, 2022 | 34,000.00 |
| Sep 30, 2022 | 100,000.00 |
| Jun 30, 2022 | -35,000.00 |
| Mar 31, 2022 | 471,000.00 |
| Sep 30, 2021 | 5,000.00 |
| Mar 31, 2021 | 713,000.00 |
| Mar 31, 2018 | 50,000.00 |